Detailed instructions for venetoclax/venetoclax: indications, usage, dosage and precautions

Venetoclax is an oral BCL-2 inhibitor mainly used to treat patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). By specifically inhibiting BCL-2 protein, venetoclax promotes programmed death (apoptosis) of tumor cells, thereby inhibiting the proliferation and survival of cancer cells. The drug provides a new therapeutic avenue for anti-cancer treatment, especially for patients with refractory or relapsed CLL and SLL.

1. Indications

The main indications for venetoclax are the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Both diseases are malignancies of the lymphatic system and usually manifest as abnormal lymphocyte proliferation. CLL is the most common type of leukemia in adults, while SLL is a special type of CLL. The two have many clinical similarities. Venetoclax is particularly suitable for patients with a history of previous treatment and poor response to standard treatments, especially when the disease relapses or becomes drug-resistant. The use of Venetoclax can effectively improve the patient's treatment response.

In addition, venetoclax is also used to treat patients with acute myeloid leukemia (AML), especially those with specific mutations or who fail to achieve remission after chemotherapy. When used in combination with other chemotherapy drugs, venetoclax can enhance the apoptosis of cancer cells, thereby providing better therapeutic effects.

2. Usage and dosage

The use of venetoclax needs to be adjusted according to the patient's condition, especially in terms of starting dose and increment. According to the instructions, the starting dose of venetoclax is 20 mg once daily. The purpose of this dosage is to allow the patient's body to gradually adapt to the drug and to reduce possible adverse reactions that may result from rapid increases in dosage. After one week of gradual increases, the dose of venetoclax can be gradually increased up to a maximum daily dose of 400 mg. Specific dosage adjustments are usually determined by the physician based on the patient's tolerance, and dosage increases should follow the physician's guidance and strict monitoring.

Venexaclava can be taken with food to improve absorption of the drug. The presence of food helps reduce the irritation of the drug to the gastrointestinal tract and facilitates the absorption of Venetoclax. Patients should ensure that they take the medicine at a fixed time every day to maintain a stable concentration of the medicine in the body for optimal efficacy. Patients should also avoid taking venetoclax while drinking grapefruit juice, as grapefruit juice may interact with the drug and affect its metabolism, thereby reducing efficacy or increasing the risk of adverse reactions.

3. Precautions

The use of Venekra requires special attention. First of all, the use of venetoclax may cause some common adverse reactions, including low white blood cell count (leukopenia), anemia, thrombocytopenia and other hematological abnormalities. These side effects are often related to the drug's mechanism of action, as venetoclax kills cancer cells by regulating the apoptotic process, but may also affect normal hematopoiesis. Therefore, patients need to have regular blood tests while taking venetoclax, especially in the early stages of treatment.

In addition, venetoclax may cause allergic reactions in patients, manifesting as rash, itching, difficulty breathing and other symptoms. If an allergic reaction occurs, the patient should stop taking the medication and seek medical advice immediately.

Venetoclax should also be used with caution in pregnant and lactating patients. Animal experiments have found that venetoclax may have adverse effects on the fetus, so pregnant women should avoid using the drug. It is unknown whether venetoclax is excreted in breast milk during lactation, so it is recommended to avoid breastfeeding during treatment.

Reference materials:https://www.venclexta.com/